Review
Version 1
Preserved in Portico This version is not peer-reviewed
Molecular Targeting of the Claudins Pathway.
Version 1
: Received: 20 January 2024 / Approved: 22 January 2024 / Online: 22 January 2024 (10:02:04 CET)
How to cite: Hana, C.; Thaw Dar, N. N.; Galo Venegas, M.; Vulfovich, M. Molecular Targeting of the Claudins Pathway.. Preprints 2024, 2024011546. https://doi.org/10.20944/preprints202401.1546.v1 Hana, C.; Thaw Dar, N. N.; Galo Venegas, M.; Vulfovich, M. Molecular Targeting of the Claudins Pathway.. Preprints 2024, 2024011546. https://doi.org/10.20944/preprints202401.1546.v1
Abstract
Claudins are a family of 27 proteins that have an important role in the formation of tight junc-tions. They also have an important function in ions exchange, cell mobility, and in in the epitheli-al-to-mesenchymal transition, the latter being very important in cancer invasion and metastasis.
Therapeutic targeting of claudins has been investigated to improve cancer outcomes. Recent evi-dence shows improved outcomes when combining monoclonal antibodies against Claudin 18.2 with chemotherapy for patients with gastroesophageal junction cancer. Currently Chimeric anti-gen receptor T-cells targeting Claudin 18 are under investigation.
Keywords
Claudin; monoclonal antibodies; adenocarcinoma; targeted therapy; CAR-T cell therapy
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment